TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of $0.73, $0.70 better than the analyst estimate of $0.03. Revenue for the quarter came in at $165.82 million versus the consensus estimate of $24.75 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.